J Rheumatol 2017 Nov 15. Epub 2017 Nov 15.
From Sorbonne Universités, UPMC Univ Paris 06; Department of Rheumatology, AP-HP, Pitié Salpêtrière Hospital, Paris, France; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia; Dipartimento di Medicina e Scienze della Salute, Università degli Studi del Molise, Campobasso, Italy; Hospital Universitario La Paz, Rheumatology Department, Madrid, Spain; Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Rheumatology University Hospital Frankfurt and Project Group Translational Medicine and Pharmacology TMP, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Goethe University Frankfurt am Main, Frankfurt, Germany. This article was drafted following a roundtable discussion funded by Novartis and attended by the authors, for which they received honoraria from Novartis. L. Gossec, Professor, MD, PhD, AP-HP, Pitié Salpêtrière Hospital; D. McGonagle, Professor, PhD, FRCPI, NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine; T. Korotaeva, Professor, MD, PhD, Department of Psoriatic Arthritis, V.A. Nasonova Research Institute of Rheumatology; E. Lubrano, Aggregate Professor, MD, Academic Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise; E. de Miguel, Associate Professor, MD, PhD, Academic Rheumatology Unit, Hospital Universitario La Paz; M. Østergaard, Professor, MD, PhD, Copenhagen University Hospital, and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases; F. Behrens, MD, Head Clinical Research Rheumatology and Fraunhofer Institute IME. Address correspondence to Prof. L. Gossec, Hôpital Pitié-Salpétrière, Service de Rhumatologie, 47-83, Boulevard de l'Hôpital, 75013 Paris, France. E-mail: Full Release Article. For details see Reprints.
As in other inflammatory rheumatic diseases, the objective of psoriatic arthritis (PsA) treatment is the achievement of a defined target. Recent recommendations propose aiming for remission or low disease activity; however, a consensual definition of remission is lacking. A state of minimal disease activity (MDA) has been established and is defined by low activity assessed by tender/swollen joint counts, tender entheseal points, Psoriasis Area and Severity Index or body surface area, patient pain and global activity visual analog scale, and functional evaluation by Health Assessment Questionnaire. Read More